linjc16/ctgov huggingface dataset:
Risk Prediction of Difficult Tracheal Intubation in OSAHS Patient

Study Overview
=================
Brief Summary
-----------------
This study evaluates the risk factors for difficult tracheal intubation in in obstructive sleep apnea hypopnea syndrome(OSAHS) patients undergoing uvulo-palato-pharyngoplast(UPPP)

Detailed Description
-----------------
OSAHS patients are high risk group of difficult tracheal intubation. In clinical application, unexpected difficult tracheal intubation is not rare. Difficult airway is a significant problem to these patients and the physicans in terms of mortality and morbidity. This study collects risk factors as physical examinations（including modified Mallampati grade, neck circumference, lateral clinical craniofacial assessment and body mass index ,BMI）, Stopbang scores, polysommographic parameters (including apnea-hypopnea index, AHI and lowest SpO2, LSpO2), and special radiographic parameters in head and neck region. By using statistics method, predictive model to manage risks would be established.

Official Title
-----------------
Risk Prediction of Difficult Tracheal Intubation in Obstructive Sleep Apnea Hypopnea Syndrome Patient (OSAHS) Undergoing Uvulo-palato-pharyngoplasty

Conditions
-----------------
Difficult Intubation, Airway Obstruction

Intervention / Treatment
-----------------
* Diagnostic Test: difficult tracheal intubation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosed as OSAHS. receive UPPP under general anesthesia in Beijing Tsinghua Changgung Hospital ASA grade I or II Exclusion Criteria: ASA grade III or above had received UPPP had fore-teeth loosed obstructive sleep apnea hypopnea were caused by hypothyroidism, acromegaly, or vocal cord paralysis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| OSAHS<br>patients with OSAHS, undergoing UPPP | Diagnostic Test: difficult tracheal intubation<br>* Grade Ⅲ or Ⅳ according to Cormach-Lehane Grading of laryngoscopic view<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difficult Tracheal Intubation | Grade Ⅲ or Ⅳ according to Cormach-Lehane Grading of laryngoscopic view | 1min After tracheal intubation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
airway management, obstructive sleep apnea hypopnea syndrome, risk predictive model
Prefabricated Versus 3D-Printing Myofunctional Appliances

Study Overview
=================
Brief Summary
-----------------
The aim of this clinical study is to evaluate the dentoskeletal effects of Class II division 1 treatment in growing patients with a prefabricated myofunctional appliance versus a 3D-printing myofunctional appliance.

Detailed Description
-----------------
This study aims to investigate the dentoskeletal effects of Class II division 1 treatment in growing patients with a prefabricated myofunctional appliance versus a 3D-printing myofunctional appliance.

Official Title
-----------------
Comparison of Prefabricated Myofunctional Appliances and 3D-Printing Myofunctional Appliances in Children With Class II Division 1 Malocclusion

Conditions
-----------------
Class II Division 1 Malocclusion

Intervention / Treatment
-----------------
* Procedure: 3d-Printing Myofunctional Appliance


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Increased overjet >4 mm Skeletal Class II relationship (ANB > 4 degree) No previous orthodontic treatment Exclusion Criteria: -Craniofacial syndrome

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental Group<br>3D-print myofunctional appliance | Procedure: 3d-Printing Myofunctional Appliance<br>* To evaluate soft- and hard-tissue changes Class II division 1 tchildren with a prefabricated myofunctional appliance versus a 3D-printed myofunctional appliance.<br>|
| Active Comparator: Control Group<br>Prefabricated myfunctional appliance | Procedure: 3d-Printing Myofunctional Appliance<br>* To evaluate soft- and hard-tissue changes Class II division 1 tchildren with a prefabricated myofunctional appliance versus a 3D-printed myofunctional appliance.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of dentoskeletal changes | Dentoskeletal effects of appliances | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Myofunctional treatment, 3D-Print, Prefabricated myofunctional appliance, Class II division 1 malocclusion, Orthodontics
Oral Manifestations of Human Immunodeficiency Virus Infection in High Risk Groups

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Evaluate the development of oral manifestations of human immunodeficiency virus infection in relationship to the onset of immunologic alterations and systemic symptoms in different risk groups: gay/bisexual men, male intravenous drug users, and female intravenous drug users. II. Evaluate the immune and inflammatory response to periodontal and other microbial pathogens. III. Evaluate the bacterial species infecting the oral cavity in patients in these risk groups.

Detailed Description
-----------------
PROTOCOL OUTLINE: Patients undergo a periodontal assessment every 6 months until medically unable to continue. The oral/dental exam includes saliva and gingival crevicular fluid analysis and, as indicated, oral photographs.

Conditions
-----------------
HIV Infections, Candidiasis, Oral

Participation Criteria
=================
Eligibility Criteria
-----------------
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Human immunodeficiency virus infection (HIV) seropositive or seronegative At risk for HIV, i.e.: Gay/bisexual men Male intravenous drug users Female intravenous drug users No acquired immunodeficiency syndrome Currently enrolled in Columbia Presbyterian Medical Center protocol The Natural History and Progression of HIV Infection

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV-associated candidiasis, candidiasis, disease-related problem/condition, fungal infection, immunologic disorders and infectious disorders, infection, rare disease
Effect of N_Acetylcysteine on Liver Functions in Donors in Living Liver Transplantation

Study Overview
=================
Brief Summary
-----------------
our practice for the past 10 years we have noticed a transitional impairment of liver function (elevated liver enzymes, total and direct bilirubin, and elevated serum lactate levels) following donors' liver resection. Several drugs have been investigation on liver regeneration , proven benefit of N-Acetylcysteine (NAC) on rats with steatohpatitis

Official Title
-----------------
Effect of N_Acetylcysteine on Liver Functions in Donors in Living Donor Liver Transplantation

Conditions
-----------------
Liver Transplant; Complications

Intervention / Treatment
-----------------
* Drug: N-Acetylecysteine
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA I or II donors healthy adult Exclusion Criteria: kidney, liver disease any contraindications for organ donation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: NAC group<br>Group NC received NAC 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days | Drug: N-Acetylecysteine<br>* N-Acetylecysteine 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days<br>|
| Placebo Comparator: Control group<br>Group C (Control group) will receive ringer acetate continuous infusion at same rate for 2 days. | Drug: Placebo<br>* Ringer acetate continuous infusion at the same rate for 2 days.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum lactate |  | 24 hours postoperative |
Evaluation of the Efficacy of Restylane Silk in the Treatment of Cheek Fold (Radial Smile Lines)

Study Overview
=================
Brief Summary
-----------------
Filler study for smile lines in cheek folds

Official Title
-----------------
Evaluation of the Efficacy of Restylane Silk in the Treatment of Cheek Fold (Radial Smile Lines)

Conditions
-----------------
Smile Lines

Intervention / Treatment
-----------------
* Device: Restylane Silk


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female between 21-65 years of age Willing to comply with study visits and procedures Willingness to refrain form surgical, laser, or injectable treatments in cheek region during study Exclusion Criteria: History of trauma, acne scarring, burns, or other changes to skin in treatment area Use of botulinum toxin in the lateral cheeks/perioral region in past 6 months Use of injectable fillers in the lateral cheeks/perioral within last 2 years History of facelift in the last year History of facial nerve palsy

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Restylane Silk<br>Restylane Silk | Device: Restylane Silk<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of the Efficacy of Restylane Silk in the Treatment of Cheek folds (Radial Smile Lines) | Improvement of subjects based on 5 point global aesthetic scale (GAIS) | 6 months |
Rudolph: Nasal Microbiota With Red and Sore Nose

Study Overview
=================
Brief Summary
-----------------
This pilot study will utilize the experimental rhinovirus infection model to study changes in skin microbiota in relation to skin erythema and soreness.

Official Title
-----------------
RUDOLPH Study Nasal Microbiota and Concurrent Nose Soreness Associated With Common Cold Infection - a Pilot Using the HRV-16 Challenge Model in Healthy Subjects

Conditions
-----------------
Dermatitis

Intervention / Treatment
-----------------
* Other: Rhinovirus Challenge


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: self reported proneness to developing symptoms of nose redness and/or soreness sero-negative to HRV-16 at screening Exclusion Criteria: confirmed or self-reported allergic rhinitis history of nasal or otologic surgery use of anti-inflammatory medication, recent antibiotics or anti-histamines

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Rhinovirus Challenge<br>Challenge with HRV-16 | Other: Rhinovirus Challenge<br>* Challenge with HRV-16 virus<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| nasal microbiota composition and occurrence of nose redness and soreness during rhinovirus infection | Taxonomic classification of bacterial strains before and after HRV-16 virus for subjects with a VAS score rating >37mm | change from baseline compared to day 22 |
Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Diabetic Vitreous Hemorrhage

Study Overview
=================
Brief Summary
-----------------
Postoperative vitreous hemorrhage is a common complication after vitrectomy for proliferative diabetic retinopathy. There have been efforts to lower the incidence of postoperative vitreous hemorrhage such as preoperative bevacizumab injection. Bevacizumab (Avastin) is a potent inhibitor of angiogenesis and has been shown to decrease retinal and iris neovascularization in proliferative diabetic retinopathy. Recently there have been reports showing that preoperative bevacizumab injection could reduce intraoperative bleeding from abnormal vessels and could make surgery easier and more successful. Our hypothesis is that intraoperative bevacizumab injection could reduce postoperative vitreous hemorrhage by inhibiting the vessel formation after surgery. We started the prospective randomized comparative study to determine the effect of pre and intra-operative bevacizumab injection on postoperative vitreous hemorrhage after diabetic vitrectomy in comparison to vitrectomy without any adjuvant drug.

Official Title
-----------------
Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Diabetic Vitreous Hemorrhage

Conditions
-----------------
Recurrent, Hemorrhage

Intervention / Treatment
-----------------
* Procedure: bevacizumab injection
* Procedure: bevacizumab injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients undergoing first vitrectomy for vitreous hemorrhage secondary to proliferative diabetic retinopathy Exclusion Criteria: follow-up period of less than 3 months not first vitrectomy abnormal blood coagulation uncontrolled hypertension

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: no injection<br>no bevacizumab | |
| Experimental: experimental 2<br>bevacizumab before vitrectomy | Procedure: bevacizumab injection<br>* bevacizumab injection before vitrectomy<br>|
| Experimental: experimental 3<br>bevacizumab after vitrectomy | Procedure: bevacizumab injection<br>* bevacizumab injection after vitrectomy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vitreous hemorrhage recurrence |  | 3 months |
Is Caffeine an Environmental Modifier in Huntington's Disease?

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to establish if caffeine consumption is associated with the evolution of the disease in premanifest HD.

Official Title
-----------------
Is Caffeine an Environmental Modifier in Huntington's Disease?

Conditions
-----------------
Huntington Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HD mutation carriers (>36 CAG) premanifest (total motor UHDRS < 5) estimated time to diagnosis between 3 and 10 years adults older than 21 years (in order to exclude juvenile patients who begin the disease before 21 years) informed consent signed with a social protection Exclusion Criteria: MRI contraindication pregnant and lactating women People under guardianship, trusteeship, deprive of freedom

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in striatal volume |  | at 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Unified Huntington's Disease Rating Scale (UHDRS) | measure the change of motor scale for exposure caffeine groups | at 1 years, at 2 years | 
| SDMT -symbol digit modality test | measure the change of cognitive score for exposure caffeine groups | at 1 years, at 2 years | 
| Stroop test | measure the change of cognitive score for exposure caffeine groups | at 1 years, at 2 years | 
| PBA (problem behaviors assessment) | the PBA is a semi structured clinical interview measuring the presence, severity and frequency of 11 key behavioural symptoms. measure the change score and subscores for apathy, obsessive-compulsive disorders, irritability, anxiety and depression, | at 1 years, at 2 years | 
| score at Epworth sleepiness scale | measure the change of sleepiness scale for exposure caffeine groups | at 1 years, at 2 years | 
| MRI | measure the change of image of the whole brain and other deep gray nuclei atrophy | at 1 years, at 2 years |
Correlation Between Eye Rubbing and Keratoconus Severity in a Treatment-naive Keratoconic Population

Study Overview
=================
Brief Summary
-----------------
determination if, within a keratoconic population, strong eye rubbing was correlated with visual acuity, spherical equivalent value, biomicroscopic signs, corneal pachymetry, keratometry, and tomography classification determinating keratoconus stage.

Detailed Description
-----------------
A retrospective study was performed between november 2014 and october 2015 in the Metz Hospital Center. Were included 33 patients presenting with treatment-naive keratoconus. Patients responded to a questionnaire that assessed eye rubbing habits, family history of keratoconus, history of atopy. 2 groups were separated: group 1 constituted by 15 eyes with no eye rubbing, and group 2 constituted by 18 eyes with moderate or severe eye rubbing. The following informations were collected: best visual corrected acuity (BCVA), spherical equivalent value (SEV), corneal opacities or Vogt striae. For each eye were performed an anterior segment OCT (AS-OCT) to determine the OCT stage for keratoconus (Fourrier domain OCT classification, 2013), and a Scheimpflug camera imaging to determine the maximal keratometry (Kmax) and the minimal corneal thickness (MCT).

Conditions
-----------------
Keratoconus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients presenting with treatment-naive keratoconus. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No eye rubbing<br> | |
| with eye rubbing<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| visual acuity |  | month 1 |
A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot

Study Overview
=================
Brief Summary
-----------------
A study to compare the risk of a major bleeding in participants who received 2 different blood thinning medications following a blood clot

Official Title
-----------------
Risk of Major Bleeding Associated With Apixaban Verses Warfarin in the Treatment of Venous Thromboembolism in US Clinical Practice

Conditions
-----------------
Venous Thromboembolism (VTE)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: An acute-care inpatient encounter with a principal or secondarydiagnosis of VTE, or an ambulatory-care encounter with any diagnosis of VTE An outpatient pharmacy claim for apixaban or warfarin during the 30-day period following the index encounter Continuous and comprehensive medical/drug coverage for ≥6 months preceding the index encounter Exclusion Criteria: Evidence of a trial fibrillation/flutter or chemotherapy/radiation therapy for malignancy (other than non-melanoma skin cancer) during 6-month period preceding first receipt of index therapy Evidence of VTE(VTE event)during 6-month period preceding index encounter Evidence of malignancy (other than non-melanoma skin cancer) during 90-day period preceding first receipt of index therapy Other protocol defined inclusion/exclusion criteria could apply

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Participants treated with apixaban<br> | |
| Participants treated with warfarin<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of major bleeding in participants treated with apixaban |  | 2 years | 
| Incidence of major bleeding in participants treated with warfarin |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of clinically relevant non-major bleeding event in participants treated with apixaban |  | 2 years | 
| Incidence of clinically relevant non-major bleeding event in participants treated with warfarin |  | 2 years | 
| Incidence of recurrent VTE in participants treated with apixaban |  | 2 years | 
| Incidence of recurrent VTE in participants treated with warfarin |  | 2 years |